DOJ Will Not Challenge Sharing of Information on Monoclonal Antibody Manufacturing

The Department of Justice (DOJ) said it will not take antitrust action against drugmakers for sharing information as they scale up manufacturing of monoclonal antibodies for the treatment of COVID-19.

In response to a request from Eli Lilly, AbCellera, Amgen, AstraZeneca, Genentech and GlaxoSmithKline, DOJ said the companies may share the information as it is “unlikely to harm competition because the likely result is that the information exchange will expand output of these critical treatments.”

The companies have promised not to share information on the price of the treatments.